国际皮肤性病学杂志    2005 31 (6): 348-351   ISSN: 2096-5540  CN: 32-1880/R   关节病性银屑病发病机制及生物制剂治疗的进展 陆威, 劳力民 浙江大学医学院附属第二医院皮肤科 杭州 310009 收稿日期 2005-04-07  修回日期 null  网络版发布日期 null 参考文献  [1] Costello P, Bresnihan B, O'Farrelly C, et al. Predominance of CD8+T lymphocytes in psoriatic arthritis. J Rheumatol, 1999, 26:1117. [2] Veale DJ, Ritchlin C, FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis, 2005, 64(Suppl 2):ii26. [3] Trembath RC, Clough RL, Rosbotham JL, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet, 1997, 6:813-820. [4] Mease PJ, Antoni CE. Psoriatic arthritis treatment:biological re sponse modifiers. Ann Rheum Dis, 2005, 64(Suppl 2):ii78-82. [5] Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis. Ann Rheum Dis, 2001, 60 (Suppl 1):146. [6] Wanke LA, Gottlieb AB, Mease PJ, et al. Etanercept (Enbrel) improves health-related quality of. life in patients with psoriatic arthritis. 2002, 46(Suppl 9):S76. [7] Ory P, Sharp JT, Salonen D, et al. Etanercept (Enbrel) inhibits radiographic progression in patients with psoriatic arthritis. Arthritis Rheum, 2002, 46(Suppl 9):S196. [8] Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during antitumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum, 2001, 44:2862-2869. [9] Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development:twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum, 2002, 46:3151-3158. [10] Carlson E, Rothfield N. Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum, 2003, 48:1165-1166 [11] Antoni C, Kavanaugh A, Kirkham B, et al. Keystone E, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum, 2002, 46(Suppl):S381. [12] Goedkoop AY, Kraan MC, Teunissen MB, et al. Early effects of tu mour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis, 2004, 63:769-773. [13] Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med, 2000, 343:1594-1602. [14] Mease P, Gladman DD, Ritchlin CT, et al. Adalimumab therapy in patients with psoriatic arthritis:24-week results of a phase Ⅲ study. Arthritis Rheum, 2004, 50:4097. [15] Baker DE. Adalimumab:human recombinant immunoglobulin gl anti-tumor necrosis factor monoclonal antibody. Rev Gastroenterol Disord, 2004, 4:196-210. [16] Nikas SN, Drosos AA. Onercept. Serono. Curr Opin Investig Drugs, 2003, 4:1369-1376. [17] Kraan MC, van Kuijk AW, Dinant HJ, et al. Alefacept treatment in psoriatic arthritis:reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum, 2002, 46:2776-2784. [18] Gottlieb A, Krueger JG, Bright R, et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Der matol, 2000, 42:428-435. [19] Utset TO, Auger JA, Peace D, et al. Modified anti-CD3 therapy in psoriatic arthritis:a phase Ⅰ/Ⅱ clinical trial. J Rheumatol, 2002, 29:1907-1913. [20] McInnes IB, Illei GG, Danning CL, et al. IL-10 improves skin dis ease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol, 2001, 167:4075-4082. 通讯作者: